Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: DHR stock price vs L: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at L's multiple
Needs L P/E.
Implied fair value · at DHR's multiple
Needs DHR P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
DANAHER CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
LOEWS CORP · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AGILENT TECHNOLOGIES, INC.
DHR vs A
ILLUMINA, INC.
DHR vs ILMN
JOHNSON & JOHNSON
DHR vs JNJ
ABBOTT LABORATORIES
DHR vs ABT
BERKSHIRE HATHAWAY INC
DHR vs BRK-B
MARKEL GROUP INC.
DHR vs MKL
CNA FINANCIAL CORP
DHR vs CNA
AMERICAN INTERNATIONAL GROUP, INC.
DHR vs AIG
GENERAL ELECTRIC CO
DHR vs GE
3M CO
DHR vs MMM
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe DHR can sustain its premium margins and defend a materially higher multiple than both L and the DCF range imply, then hold or buy on weakness because its profitability and balance-sheet profile are stronger than L’s; otherwise, the valuation gap argues for caution.
The valuation signals are mixed: the current price of $197.93 sits near the top of the historical band ($178.14-$217.72) but far above the DCF range ($71.23-$96.37) and above L-implied range midpoint. The stated implied price from the P/E approach is $73.83, implying -62.7% downside, which points to a substantial valuation gap.
Supporting Metrics
